Co-Founding CEO – Metabolic & Inflammation Therapies
Posted 4ds ago
Employment Information
Report this job
Job expired or something wrong with this job?
Job Description
Co-founding CEO leading strategy, fundraising, and team building for NLC’s first-in-class metabolic disease biotech venture. Advancing INT-101 from preclinical development toward clinical trials.
Responsibilities:
- Define and execute the company's strategy, aligning science, operations, and business goals
- Lead seed and Series A fundraising, leveraging networks and partnerships to secure capital and strategic collaborations
- Choose and prioritize indication strategy, such as DKD, obesity, atherosclerosis, or MASH, based on opportunity, patient need, and risk
- Oversee the transition from preclinical development to IND submission and clinical development
- Build and manage the team as the company progresses
- Collaborate with Professor Ann Marie Schmidt and advisors to integrate scientific excellence with commercial strategy
- Represent the venture to investors, partners, and the scientific community
- Lead all aspects of the venture's growth from strategy-setting through advancing programs into clinical trials
Requirements:
- Proven biotech or life sciences leader with early-stage venture experience
- Successful fundraising track record
- Strong scientific and strategic understanding of metabolic diseases, such as diabetes, kidney disease, or obesity, or related areas
- Experience guiding programs through preclinical and regulatory development toward the clinic
- Ability to turn complex science into a clear, fundable business plan
- Exceptional communication and relationship-building skills with investors, advisors, and diverse stakeholders
- Hands-on, adaptable leadership suited to dynamic startup environments
- Integrity, credibility, and a collaborative mindset
- ASAP preferred, with Q4 2026 at the latest start date
Benefits:
- Equity-only compensation, transitioning to salary after fundraising
- Part-time commitment to start, with greater time commitment expected as the company scales








